What is Aubrai by Bio (AUBRAI)?

Quick Facts

• Token: AUBRAI
• Blockchain: Base (Ethereum Layer-2)
• Co-developed by: Bio Protocol and VitaDAO
• Core focus: Decentralized AI agent for longevity science
• Scientific advisor: Dr. Aubrey de Grey
• Token utility: Governance, research funding, revenue sharing
• Key mechanism: Proof-of-Invention (POI) for on-chain hypothesis records
• Launched: August 2025 via Bio Launchpad Ignition Sale

Introduction

Aubrai by Bio (AUBRAI) is the governance and utility token powering Aubrai — described as the world's first decentralized BioAgent. The project sits at the intersection of artificial intelligence, blockchain infrastructure, and longevity science, with the goal of accelerating research into aging and human lifespan extension.

Unlike centralized scientific AI tools from large technology companies, Aubrai integrates directly with blockchain to enable open coordination, decentralized funding, and shared ownership of scientific discoveries.

History & Background

Aubrai was co-developed by Bio Protocol and VitaDAO, two prominent decentralized science (DeSci) organizations. Bio Protocol founder Paul Kohlhaas spearheaded the initiative alongside the global longevity community.

The project drew its foundational knowledge from thousands of private lab notes, internal communications, and unpublished research insights from the lab of renowned gerontologist Dr. Aubrey de Grey — best known for his Strategies for Engineered Negligible Senescence (SENS) framework. The AUBRAI Ignition Sale launched in August 2025 on the Bio Launchpad and was oversubscribed more than 13 times its fundraising target.

How Aubrai by Bio Works

At its core, Aubrai functions as an on-chain AI co-scientist. It can generate and validate research hypotheses, design wet-lab experiment workflows, and securely encrypt sensitive scientific data.

A key innovation is its Proof-of-Invention (POI) system. Valid hypotheses are hashed directly on Base, creating an immutable, blockchain-verified trail of scientific progress. This ensures that contributors whose early insights shaped a discovery receive proper recognition and potential value.

The Aubrai Researcher Terminal provides a dashboard for researchers to interact with the agent, track hypotheses, and manage knowledge assets. Verified researchers can gain expedited access through the platform.

Tokenomics

The AUBRAI token is the economic backbone of the entire ecosystem. It serves three primary functions: governance over research funding and experimental direction, fee payment to bootstrap scientific experiments, and revenue sharing from monetized knowledge assets.

AUBRAI holders become permanent stakeholders in the agent's knowledge stream. When Aubrai generates revenue by providing insights, compounds, or services to pharmaceutical companies and research organizations, that value flows back to token holders. Validated research data can also be tokenized as on-chain IP-Tokens, representing intellectual property in a tradeable, decentralized format.

The token launched on Base via the Bio Launchpad and is tradeable on decentralized exchanges, primarily through Aerodrome SlipStream.

Ecosystem & Use Cases

The Aubrai ecosystem connects multiple layers of the DeSci and AI space. It integrates with leading AI platforms, open-source research tools such as OpenScholar and HuggingFace, and Molecule's POI infrastructure.

The flagship research initiative is the Robust Mouse Rejuvenation (RMR2) project — an ambitious study aimed at doubling the remaining lifespan of middle-aged mice. Success in RMR2 could serve as a landmark proof-of-concept for multi-target rejuvenation therapies.

Bio Protocol also plans to expand the BioAgent model to other scientific domains, enabling BioDAOs and individual researchers to deploy their own on-chain AI agents.

Team, Governance & Community

Aubrai was built under the leadership of Paul Kohlhaas, founder of Bio Protocol. The broader team emphasizes a decentralized, community-first approach, with communications primarily through the official aubr.ai website and social channels.

Token holders govern research priorities and funding decisions. The community includes researchers, longevity enthusiasts, DeSci builders, and Web3 participants — all aligned around the shared mission of fighting aging.

Advantages

• First-mover position in on-chain AI agents for longevity science
• Credible scientific foundation built on Dr. Aubrey de Grey's research and VitaDAO's DeSci expertise
• Proof-of-Invention creates verifiable, immutable records of scientific contributions
• Revenue-sharing model aligns token holders with real-world research outcomes
• Base blockchain provides low fees and scalability for frequent on-chain interactions

Risks & Challenges

• Early-stage science: Translating AI-generated hypotheses to clinical outcomes is a long and uncertain process
• Smart contract risk: Noted third-party warnings indicate the contract creator retains certain administrative privileges
• Low liquidity: Trading volumes remain modest, making the token susceptible to high volatility
• Regulatory uncertainty: Tokenized intellectual property and pharmaceutical data monetization are largely uncharted legal territory
• Dependency on partnerships: The ecosystem relies on continued collaboration with VitaDAO, Molecule, and academic researchers

Long-Term Vision

Aubrai's long-term ambition is to become a self-sustaining, fully autonomous on-chain AI scientist. The roadmap points toward permissionless participation in future Ignition Sales, a growing roster of BioAgents across scientific disciplines, and the commercialization of validated research as on-chain IP assets.

By merging decentralized governance with cutting-edge AI and longevity research, Aubrai aims to bridge the chronic funding gap in translational science — creating a model where open, incentive-aligned coordination between researchers, token holders, and the pharmaceutical industry could redefine how breakthroughs are discovered and shared.